News

Femara tablets had US sales of approximately $326 million for the same strength for 2006, according to IMS Health. However, Novartis plans to defend its intellectual property rights

ARRY-520 is a potent kinesin spindle protein inhibitor that caused marked tumor regression in preclinical models of human cancer at tolerated doses, often leading to complete, durable responses.

Preliminary results of the clinical study showed that six months of treatment with doses of Iplex up to 1mg/kg/day in six patients met the primary study endpoints of

The schedule II designator is applied to drugs considered to have a high likelihood of being abused and additional prescribing safeguards are put in place. Shire said that

Tysabri was temporarily withdrawn from the US market in 2005 after three cases of progressive multifocal leukoencephalopathy, or PML, in patients taking it in clinical trials. Two of

The antibody was generated using Medarex’s UltiMAb technology and is the second UltiMAb-derived antibody to be advanced into phase II clinical development by Amgen. Medarex may receive future

Symptomatic venous thromboembolism (VTE) is the formation of a blood clot that can travel from a leg vein to the lung, with potentially fatal results. Fragmin is the

The proposed labeling changes also state that studies did not show this increased risk in adults older than 24, and that adults ages 65 and older taking antidepressants

The phase II clinical trial will be based at the Texas Heart Institute, and will follow a similar protocol to the one used by the same investigators in